X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

September 27, 2022

https://www.globenewswire.com/news-release/2022/09/27/2523238/0/en/X4-Pharmaceuticals-Announces-New-Positive-Phase-1b-Data-Supporting-Mavorixafor-s-Broad-Potential-in-Chronic-Neutropenia-CN.html

100% of study participants (n=25) achieved robust responses to oral mavorixafor

100% of neutropenic participants (n=14) achieved normalized neutrophil counts

Read more at globenewswire.com

Related news for (XFOR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.